secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001493152-23-041987
Event type: other_material
Sentiment:  positive
Materiality: 0.82
Item codes: 1.01, 2.03, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharma licenses Ketamir-2, gets $3M loan from MIRALOGX; appoints new director
--------------------------------------------------------------------------------

- Exclusive license for Ketamir-2 (oral ketamine analog) in North America; $100k upfront, 8% royalties.
- MIRALOGX provides $3M line of credit to fund Ketamir-2 IND development; 8% interest, one-year term.
- MIRA issues warrant for 700k shares at $2.00 per share, exercisable through Nov 15, 2028.
- Michael Jerman appointed to Board, Audit Committee, and Compensation Committee effective Nov 14, 2023.
- DEA determined Ketamir-2 is not a controlled substance; potential for home self-administration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/0001493152-23-041987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315223041987/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer